% | $
Quotes you view appear here for quick access.

InterMune, AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wall_st_knight_mare wall_st_knight_mare Aug 20, 2012 7:12 PM Flag

    Can Someone Tell Me about this company


    InterMune loss from continuing operations widened to $50.9 million, or 78 cents per share, in the second quarter from $41.3 million, or 70 cents per share, a year earlier.

    Including the one-time payment from the sale of Actimmune, the company posted a net profit of $490,000, or 1 cent per share.

    Esbriet, which was rejected by the U.S. Food and Drug Administration in May 2010, is currently being studied in a late-stage trial.

    InterMune expects to complete enrollment by the year end. William Blair analyst Xu expects data from the trial by 2014.

    SortNewest  |  Oldest  |  Most Replied Expand all replies